FLUORETH-LAD
Identifiers
  • (6aR,9R)-N,N-diethyl-7-(2-fluoroethyl)-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
PubChem CID
Chemical and physical data
FormulaC21H26FN3O
Molar mass355.457 g·mol−1
3D model (JSmol)
  • CCN(CC)C(=O)[C@H]1CN([C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1)CCF
  • InChI=1S/C21H26FN3O/c1-3-24(4-2)21(26)15-10-17-16-6-5-7-18-20(16)14(12-23-18)11-19(17)25(13-15)9-8-22/h5-7,10,12,15,19,23H,3-4,8-9,11,13H2,1-2H3/t15-,19-/m1/s1
  • Key:UYFDKYZWVLEHQH-DNVCBOLYSA-N

FLUORETH-LAD is a lysergamide derivative. It was first proposed by Alexander and Ann Shulgin in their book TiHKAL,[1] but was never synthesised by Shulgin. Synthesis and activity data for the compound were first reported in a 2022 patent by Matthias Grill, in which pharmacological testing showed it to have similar affinity to LSD at some targets such as the 5-HT1A and 5-HT2A serotonin receptors, but much lower affinity at other targets such as 5-HT2C and at dopamine receptors, giving it comparatively greater selectivity compared to LSD.[2]

See also

References

  1. ↑ TIHKAL #51: PRO-LAD
  2. ↑ WO 2022/008627, Grill M, "Improved Method for the Production of Lysergic Acid Diethylamide (LSD) and Novel Derivatives thereof."



This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.